News & Insights Across Asia
Chinese Premier Li Qiang has urged strict regulation of enterprise inspections to stabilize market expectations and enhance governance, following a State Council meeting that approved key guidelines and reforms.
AstraZeneca plans to launch over 100 new medicines in China within five years, strengthening collaboration through its Shanghai R&D center, according to EVP Sharon Barr.
AstraZeneca amplifies its presence in China with significant investments in Wuxi and Qingdao, focusing on innovation and R&D to advance global health and economic growth.
The over-prescription of opioids in the U.S. has led to a major addiction crisis, with pharmaceutical companies accused of underplaying addiction risks while exaggerating benefits.